Stock SGRL6 SHREE GANESH REMEDIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shree Ganesh Remedies Limited

Equities

SGRL6

INE414Y01015

Biotechnology & Medical Research

Market Closed - Bombay S.E.
Other stock markets
 11:00:56 21/06/2024 BST 		5-day change 1st Jan Change
837.7 INR +0.84% Intraday chart for Shree Ganesh Remedies Limited -1.02% +22.70%
06-01 Shree Ganesh Remedies Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
04-17 Shree Ganesh Remedies Begins Trial Run of Plant in Gujarat, India MT

Valuation

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Capitalization 1 403.7 485.8 650.4 3,352 3,561 3,097
Enterprise Value (EV) 1 299.2 443.3 641.8 3,288 3,522 3,321
P/E ratio 7.33 x 7.79 x 6.21 x 34.4 x 26.6 x 18 x
Yield 2.22% 2.31% 2.07% 0.52% 0.17% 0.2%
Capitalization / Revenue 1.48 x 1.38 x 1 x 6.83 x 5 x 3.43 x
EV / Revenue 1.1 x 1.26 x 0.99 x 6.7 x 4.94 x 3.68 x
EV / EBITDA 5.47 x 4.87 x 4.68 x 23.4 x 19.1 x 13.8 x
EV / FCF 22.3 x 15.2 x 19.7 x 37.6 x -48.9 x -8.06 x
FCF Yield 4.49% 6.58% 5.08% 2.66% -2.04% -12.4%
Price to Book 1.41 x 1.44 x 1.54 x 6.7 x 5.78 x 3.6 x
Nbr of stocks (in thousands) 12,008 12,008 12,008 12,008 12,007 12,847
Reference price 2 33.62 40.46 54.17 279.1 296.6 249.6
Announcement Date 08/10/18 02/08/19 26/08/20 16/08/21 05/09/22 26/08/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: März 2018 2019 2020 2021 2022 2023
Net sales 1 272.6 353.1 647.7 490.8 712.9 902.2
EBITDA 1 54.74 90.95 137.1 140.5 184.5 240.8
EBIT 1 48.74 80.27 113.6 112.7 152.6 204.8
Operating Margin 17.88% 22.73% 17.54% 22.95% 21.41% 22.7%
Earnings before Tax (EBT) 1 64.76 86.66 135.9 129.5 180.1 225.8
Net income 1 46.87 62.35 104.7 97.54 134 170.2
Net margin 17.19% 17.66% 16.16% 19.87% 18.8% 18.87%
EPS 2 4.587 5.192 8.719 8.123 11.16 13.86
Free Cash Flow 1 13.43 29.18 32.57 87.5 -72 -412.1
FCF margin 4.93% 8.26% 5.03% 17.83% -10.1% -45.67%
FCF Conversion (EBITDA) 24.53% 32.09% 23.76% 62.28% - -
FCF Conversion (Net income) 28.65% 46.8% 31.11% 89.71% - -
Dividend per Share 2 0.7471 0.9339 1.121 1.458 0.5000 0.5000
Announcement Date 08/10/18 02/08/19 26/08/20 16/08/21 05/09/22 26/08/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 224
Net Cash position 1 105 42.5 8.63 63.7 38.8 -
Leverage (Debt/EBITDA) - - - - - 0.9286 x
Free Cash Flow 1 13.4 29.2 32.6 87.5 -72 -412
ROE (net income / shareholders' equity) 20.8% 20% 27.5% 21.1% 24% 22.6%
ROA (Net income/ Total Assets) 10.7% 13% 14.7% 12.2% 13.9% 11.6%
Assets 1 436.6 478.3 712.6 802.6 966.6 1,468
Book Value Per Share 2 23.90 28.20 35.10 41.60 51.30 69.20
Cash Flow per Share 2 7.100 0.8300 1.940 2.890 3.230 8.680
Capex - 0.99 0.44 0.09 153 516
Capex / Sales - 0.28% 0.07% 0.02% 21.5% 57.18%
Announcement Date 08/10/18 02/08/19 26/08/20 16/08/21 05/09/22 26/08/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
SHREE GANESH REMEDIES LIMITED Stock Shree Ganesh Remedies Limited
+22.70% 129M
MODERNA, INC. Stock Moderna, Inc.
+34.14% 51.12B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-6.54% 39.4B
LONZA GROUP AG Stock Lonza Group AG
+34.92% 38.48B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.62% 26.36B
CELLTRION, INC. Stock Celltrion, Inc.
-12.11% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-13.43% 20.96B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+43.73% 14.02B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.81% 12.49B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-4.54% 11.61B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SGRL6 Stock
  4. Financials Shree Ganesh Remedies Limited